​

Cullinan Therapeutics Stock (NASDAQ:CGEM)

ForecastOwnershipFinancialsChart
Cullinan Therapeutics by TradingView

Previous Close

$14.91

52W Range

$5.68 - $16.74

50D Avg

$12.52

200D Avg

$9.25

Market Cap

$845.38M

Avg Vol (3M)

$831.96K

Beta

-0.16

Div Yield

-

CGEM Company Profile

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

111

IPO Date

Jan 08, 2021

Website

CGEM Performance

CGEM Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-241.65M$-196.92M$-191.09M
Net Income$-219.88M$-167.38M$-153.16M
EBITDA$-241.65M$-167.15M$-190.34M
Basic EPS-$-3.11$-3.69
Diluted EPS-$-3.11$-3.69

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
SYSo-Young International Inc.
CBLLCeriBell, Inc.
BCYCBicycle Therapeutics plc
ADCTADC Therapeutics S.A.
OMEROmeros Corporation
NMRANeumora Therapeutics, Inc. Common Stock
RAPTRAPT Therapeutics, Inc.
LABStandard BioTools Inc.
EHABEnhabit, Inc.
VREXVarex Imaging Corporation